Professor; Director Cancer Cellular Immunotherapy
Area of Interest
My scientific training is in hematology and immunology. Since 2000, I have exploited my expertise for the treatment of malignancies using gene modified T lymphocytes. I have a particular interest in strategies that redirect the antigen specificity of T lymphocytes and overcome tumor inhibitory mechanisms, such as development of chimeric antigen receptors, transgenic T-cell receptor, cytokine and cytokine receptor expressions from preclinical assessment to clinical application.